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Background: It is estimated that 29% of deaths in Australia are caused by malignant disease each year and can be
expected to increase with population ageing. In advanced cancer, the prevalence of fatigue is high at 70–90%, and
can be related to the disease and/or the treatment. The negative impact of fatigue on function (physical, mental,
social and spiritual) and quality of life is substantial for many palliative patients as well as their families/carers.
Method/design: This paper describes the design of single patient trials (n-of-1 s or SPTs) of a psychostimulant,
methylphenidate hydrochloride (MPH) (5 mg bd), compared to placebo as a treatment for fatigue, with a
population estimate of the benefit by the aggregation of multiple SPTs. Forty patients who have advanced
cancer will be enrolled through specialist palliative care services in Australia. Patients will complete up to 3
cycles of treatment. Each cycle is 6 days long and has 3 days treatment and 3 days placebo. The order of
treatment and placebo is randomly allocated for each cycle. The primary outcome is a reduction in fatigue
severity as measured by the Functional Assessment of Cancer Therapy-fatigue subscale (FACIT-F). Secondary
outcomes include adverse events, quality of life, additional fatigue assessments, depression and Australian
Karnovsky Performance Scale.
Discussion: This study will provide high-level evidence using a novel methodological approach about the
effectiveness of psychostimulants for cancer-related fatigue. If effective, the findings will guide clinical practice
in reducing this prevalent condition to improve function and quality of life.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12609000794202
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Cancer is the second most common cause of death in
Australia, accounting for 29% of all death in 2007 [1].
Predictably, the prevalence of cancer will increase with
the ageing of the population. In Australia, the number of
people aged 80 years and over will increase from 3.6% in
2006 to 7.9% by 2036 [2]. Therefore, the role of palliative* Correspondence: h.senior@uq.edu.au
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reproduction in any medium, provided the orcare in caring for these patients will become increa-
singly important.
Cancer-related fatigue is defined as a “distressing, persist-
ent, subjective sense of physical, emotional and/or cogni-
tive tiredness or exhaustion, related to cancer or cancer
treatment, which is not proportional to recent activity and
interferes with normal functioning” [3]. In advanced can-
cer, the prevalence of fatigue is high at 70–90% [4-6]. Fa-
tigue can have a high impact on function (physical, mental,
social and spiritual) and quality of life (QOL) for many pal-
liative patients and hence their families/carers. A positiveLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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should occur with a reduction in fatigue [7].
Methylphenidate hydrochloride (MPH) is a central ner-
vous system stimulant. It blocks the dopamine transporter
in the pre-synaptic cell membrane, thereby raising extracel-
lular dopamine (D2) levels [8]. Its primary indication is in
the treatment of Attention Deficit Hyperactivity Disorder.
The USA National Cancer Care Network Guidelines on
cancer-related fatigue recommend the use of psycho-
stimulants for fatigue after ruling out other causes of fa-
tigue, and note that the effectiveness of psychostimulants
for fatigue remains investigational [3]. When the drugs are
used in carefully titrated doses, side effect profiles have gen-
erally been found to be low and reverse rapidly due to the
drugs’ short half-life.
N-of-1 trials in palliative care
N-of-1 trials are multiple-cycle, double blind, placebo-
controlled crossover trials using standardized measures of
effect. They are usually used for testing the effectiveness of
medicines in individual patients. The randomisation order
is independently generated for each patient. At the end of
the trial the order is revealed, and the patient response is
compared against the presence or absence of the test treat-
ment. N-of-1 trials provide the strongest evidence possible
about the efficacy of a treatment in an individual patient
[9]. Aggregating the results of many n-of-1 trials allows a
treatment effect to be ascertained for a patient population.
For details on aggregated n-of-1 methodology refer to
Zucker et al. 1997, Schluter and Ware 2005 and Nikles
et al. 2011 [10-12].
Methods/design
Study aims
The hypothesis to be tested is whether central nervous sys-
tem stimulant therapy with MPH will improve fatigue in
patients with advanced life-limiting disease compared to
placebo. The primary objective is to determine a population
and individual patient estimate of the efficacy of MPH in al-
leviating fatigue with advanced cancer. Secondary aims are
to assess the frequency and severity of any side effects asso-
ciated with the use of MPH in this population, and to pro-
vide process evaluation on the feasibility of SPTs as a
routine means of conducting clinical trials in palliative care.
Study design
This study is a series of Randomised, Double-Blind,
Placebo-Controlled, Multi-Centre, Single Patient (N-of-1)
Trials. In this SPT, the participant undergoes 3 pairs of
treatment periods. As MPH has a short half-life (4 hours),
the clinical effect is achieved quickly and a steady state is
reached after 5 half-lives (i.e. 20 hours). This allows a treat-
ment period of 3 days (and 6 days for each treatment pair),
making a total of 18 days for patients to complete the fulltrial. No assessment of efficacy is taken on the first day of
each 3-day period to allow for medication wash-out. In
each cycle, drugs are randomly allocated to patients with
both investigators and patient blinded (see Figure 1). At
the end of the trial, the order of medications within each of
the three cycles is unmasked. Repeated results from the
outcome assessments in the same direction favouring the
treatment can be reported in terms of a probability that
the result is true.
Study population and recruitment
Patients who are either admitted to a hospital ward or out-
patients will be recruited from participating sites of the
Palliative Care Clinical Studies Collaborative, namely, six
specialist palliative care services in two states of Australia.
Patients will be invited to participate if they are aged ≥
18 years and have advanced cancer of any type. They must
also have a Australian Karnofsky Performance Scale (AKPS)
score ≥ 40, a fatigue score ≥ 4/10 by a single screening ques-
tionnaire adopted from the NCCN cancer-related fatigue
guidelines, [13] a stable treatment regimen (including ste-
roids) for at least 48 hours and likely to remain stable
throughout the trial period, no planned treatment likely to
influence fatigue during the trial, no change in thyroxine
therapy or antidepressant therapy in the 3 weeks prior and
an ability to understand all study requirements. Exclusion
criteria are: unable to comprehend written English, confu-
sion or mini-mental state examination (MMSE) < 24, un-
stable symptoms or disease such that the patient is unlikely
to be able to complete all study requirements, history of se-
vere ischaemic heart disease, uncontrolled cardiac arrhyth-
mias or hypertension, electrolyte imbalances (Na, K, Mg,
Ca) where attempt at correction is being considered, an-
aemia for which a blood transfusion is indicated, erythro-
poietin therapy in the previous 2 weeks.
Primary outcome
Patients will complete a daily diary which includes the Func-
tional Assessment of Cancer Therapy-Fatigue (FACIT-F)
sub-scale [14,15]. The primary outcome is a change in the
mean FACIT-F scores for patients on MPH compared to
placebo. FACIT-F is a 13 question, 5 point Likert scale
with a possible range of scores from 0 to 52. It is reliable,
valid and sensitive to detecting the impact of fatigue in
cancer patients [14,15]. A three point change in the scale
is regarded as clinically significant for all cancer patients.
It has also been shown to relate to self-reported capacity
to perform everyday activities [16].
Secondary outcomes
Demographics and cancer related medical history will be
collected at baseline (age, gender, status of primary care-
giver, tumour type, year of diagnosis, sites of metastases).











Figure 1 Example of n-of-1 design schema1.
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sures (see below) and also record any side effects. Fatigue
will also be assessed by the Wu Fatigue Scale [17]. This will
be compared to results from the FACIT-F subscale. The
Wu Cancer Fatigue Scale (WCFS) is a valid and reliable
nine question, five point scale, with a range of possible
scores from five to 45. A higher score indicates greater
fatigue. Depression will be assessed using the valid and
reliable Edinburgh Depression Scale which consists of 10
items, rated on a four-point scale and includes items on
guilt, thoughts of self-harm and hopelessness [18,19]. A
higher score indicates more depression, and the tool has
been validated in patients with advanced cancer [19]. Per-
formance status will be measured at the end of the three-
day cycle using the AKPS scale which has high inter-rater
reliability and is sensitive to changes in function over time. A
score of 0 to 100 (in increments of 10) is assigned to patients
based on their ability to undertake a range of daily tasks.
Randomisation
Each cycle will be two periods of three days each for a
maximum of three cycles of 6 days. A computer gener-
ated randomisation schedule held by the pharmacy (and
not accessible to investigators) will determine the order
of medication (MPH or placebo) in each cycle. Rando-
misation is to be conducted in blocks of four to pre-
vent unblinding.
Safety reviews
In the patient diary and at each contact with a researcher,
adverse events and medication side effects will be assessed.Patients will be contacted every 3 days, (or daily if there are
any concerns) to ensure diary completion and to assess any
adverse events. The severity of the side effect will be rated
according to NCI Common Terminology Criteria for Ad-
verse Events [20]. Any rating ≥ 3 of 3 or 4 in severity will
activate cessation of the study intervention for that partici-
pant and an adverse event report to the Data and Safety
Monitoring Board (DSMB) and the ethics committees.
Common side effects are nausea, loss of appetite, anxiety,
insomnia, dry mouth, tachycardia, palpitations, and changes
in blood pressure (usually increases in adults). Infrequent
side effects are movement disorders, tics, rash, weight loss,
and growth retardation in children. Rare side effects include
psychosis, neuroleptic malignant syndrome, and liver dys-
function [8]. Compliance with trial medication will be
assessed by capsule count. A cycle will only be included
in the analysis if all capsules for that cycle (6 days) have
been taken.Treatment, concomitant medications and compliance
To inform this trial, a dose finding study was undertaken
in 10 patients with fatigue and advanced cancer to assess
the optimal dose that has an effect on fatigue [21]. Partici-
pants were commenced on a dose of 5 mg daily and the
dose was increased every 3 days to a maximum of 15 mg
bd. The study found that the optimal dose was 5 mg twice
daily, above which there was only limited improvement
in fatigue.
Patients will randomly be assigned each of the follow-
ing two medications in each of the three cycles.
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tablet bd by mouth.
2. Placebo: visually matched capsule bd by mouth.
MPH and placebo capsules will be prepared and pack-
aged by the Pharmacy Production Unit at the lead hospital’s
pharmacy in Brisbane, and couriered to the participating
sites. Pre-packaged, numbered medication packs will be
available at each site, and the packages specified by the
randomisation will be allocated to the patient by the site
hospital pharmacy upon prescription from the study inves-
tigator. Trial participants are to continue their current con-
comitant medicine regimen. Any changes in concomitant
medications are to be documented. Participants are re-
quested to bring all medication bottles and unused capsules
back to clinic. Compliance will be assessed by capsule
count. All unused study medicine will be destroyed by the
hospital pharmacy on completion of study participation.Post-trial treatment for individual patients
Once the analysis has been completed for an individual
patient at the end of the trial for a specific patient, a re-
port detailing the single patient trial findings and recom-
mendations is sent to the palliative care specialist for the
patient. An appointment is made for the patient to dis-
cuss the results with their doctor and to make a decision
regarding further treatment with MPH.Statistical considerations
Sample size
In a double-blind placebo controlled variable dose RCT
trial of MPH (5–20 mg/day over 7 days) for advanced
cancer-related fatigue, the mean baseline FACIT-F score
was 17.0 (standard deviation (SD) = 7.9) and mean change
in FACIT-F score from baseline for placebo was 7.5 (SD =
11.3) [22]. Utilising these estimates, sample size calculations
reveal that in a conventional RCT, n = 33 patients per group
would be required to detect a mean difference of 8 on the
FACIT-F scale between treatment arms with 5% signifi-
cance (2-sided) and 80% power. With 30% attrition, this
would increase to 47 patients per group. Using this same
information, except based on the three-cycle aggregated
SPT design and assuming there is no period effect, within-
patient serial correlation, or treatment × time interaction,
the study statistician (PS) designed a computer-based simu-
lation model in SAS statistical software (ver 9.2, SAS Insti-
tute Inc., Cary, NC, USA) to estimate the required sample
size . Assuming 60% completion of one cycle, 50% two, and
45% completion of all three cycles, then simulations of size
N = 10,000 yielded that approximately 21 patients were re-
quired at 5% significance and 80% power. To account for
likely within-patient serial correlation and potentially worse
attrition, the study plans to recruit 40 patients.Statistical analysis
There are a number of statistical methods proposed for
the analysis of SPTs, with hierarchical Bayesian statistical
methods being considered the most appropriate.
The advantages of a Bayesian approach over normal
frequentist statistical methods are discussed in detail in
Zucker et al. 1997, Schluter and Ware 2005 and Nikles
et al. 2011 [10-12]. Briefly, these methods allow: (a) both in-
dividual and aggregate analyses to be simultaneously and
coherently undertaken–even when the number of com-
pleted cycles between patients is variable, (b) they exploit
and accommodate natural hierarchies and serial correla-
tions within the study (such as clustering by physician, set-
ting, or location), (c) the outcome variable of interest can
take any functional form, (d) confounding variables can
easily be introduced, (e) they naturally allow the incorpor-
ation of any relevant trial information that may be sourced
from elsewhere, and (f) they produce sensible estimates
and confidence intervals [10-12]. Most proposed methods
for combining simple measures of the difference between
active and placebo treatments cannot make such assertions
and often assume a normal distribution of differences; an
often rich assumption, [12,23] especially with the frequent
use of nominal scales [11]. However, testing or the valid-
ation of this assumption can be hampered by the small
number of cycles a patient may undertake, and so violations
are often undetected. Consequences of these assumption
violations are imprecise, incoherent and/or impossible esti-
mates; all of which considerably reduce the utility of any
pursuant statistical estimate or inference. Bayesian methods
are still largely ignored in the medical literature–as there is
the perception that such methods are difficult to employ.
However, as can be seen in the programme code given by
Schluter and Ware, using a freely downloaded computer
software package (WinBUGS), this argument holds less
ground in modern times.
Ethical considerations
Ethical approval
Written approvals have been obtained from relevant Hos-
pital Research Ethics Committees (Hunter New England
HREC, Gold Coast Health Service District HREC, Mater
Health Services HREC, Royal Brisbane and Women’s Hos-
pital HREC, St/Vincent’s and Holy Spirit Health HREC)
and The University of Queensland Medical Research Ethics
Committee prior to study commencement. Informed con-
sent is required for patient trial registration. All patients re-
ceive a re-identifiable registration number for the trial
CRFs and database.
Trial withdrawal and discontinuation of trial medication
Patients can withdraw from the trial at any time without
reason or impact on usual care and reason for withdrawal
is recorded. The study drug will be discontinued and the
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adverse event or the participant is not well enough to con-
tinue the study medicine. If the study drug is discontinued
following some unexpected event, it can be restarted at a
later date, assuming the participant consents. Only data
from completed cycles will be included in the population
analysis. The trial will be stopped if DSMB recommend
stoppage due to safety concerns.
Discussion
Cancer is the second most common cause of death in
Australia, and the incidence is likely to increase with an
ageing population. A prevalent condition associated with
cancer and/or its treatment is fatigue with negative conse-
quences on patients and carers quality of life and function.
Evidence for the use of psychostimulants in managing fa-
tigue in cancer is still largely based on non-randomized
studies or small studies and in patients with a range of can-
cer severity (eg [24-26]). In trials, there are mixed results,
with one prophylactic placebo-controlled trial of methyl-
phenidate in people undergoing radiotherapy for brain tu-
mors showing no effect in preventing fatigue [27]. Another
phase III trial of methylphenidate in patients receiving
chemotherapy also found no effect on cancer-related fa-
tigue or QOL, except after a subset analysis for those with
more severe fatigue and/or advanced disease [28]. In con-
trast, Lower et al. in their placebo controlled trial in cancer
patients undergoing chemotherapy found a significant im-
provement in fatigue symptoms [29]. A recent systematic
review concluded that preliminary evidence provides partial
evidence for the use of psychostimulants to treat cancer-
related fatigue [26]. Given the uncertainty around the bene-
fit of psychostimulants in the management of fatigue in
patients with advanced cancer, and the high prevalence of
this problem and its negative impact on QOL of many pa-
tients and their families/carers, it is imperative that further
evidence is obtained from well-designed studies [26].
Due to the challenges in recruiting patients with ad-
vanced disease into trials, we propose an alternative ap-
proach to RCTs while providing high-level evidence on
treatment effects. Aggregated SPTs, due to their cross-
over design, reduce the required sample size while con-
trolling for confounding.
The main limitation of SPTs in the palliative care popula-
tion is the possibility of disease progression causing dif-
ferences between arms of a test cycle. This problem is
addressed in the methodology. SPTs are appropriate where
(a) the condition remains relatively stable during follow-up
period (to the extent that changes observed within repli-
cate pairs cannot be attributed to disease progression) (b)
the medication does not alter the pathophysiology of the
condition; (c) the medication has a short half-life; and (d)
there is validated measurement of effect [9]. In palliative
care, single crossover trials have been published [30], butthere are few multiple crossover formal SPTs [31]. MPH
meets the criteria for utilising an n-of-1 trial method in ad-
vanced cancer as (a) the cancer fatigue should remain
stable as a short period of follow-up, (b) there is no re-
sidual impact on the target symptom once excreted, (c) it
has a short half-life and (d) validated measures are used.
SPTs offer two advantages not currently available in
palliative care. The first is that the individual patient re-
ceives the strongest evidence possible about the effect-
iveness of the test treatment against the comparator for
them. Treatment can be tailored to the individual to
allow treatment recommendations. The second is that a
series of such individual trials of a given treatment can
yield an estimate of the population effect comparable to
a RCT, but requiring substantially less numbers of par-
ticipants to gather that evidence, which in a difficult to
recruit population is an important design strength.
This study is the first study to employ aggregated,
multiple n-of-1 s in palliative care research, and will not
only assess the effectiveness of methylphenidate on fa-
tigue reduction, but will also evaluate the methodo-
logical and analytical approaches to conducting SPTs in
this population. SPTs require evidence on the proof of
concept, and establishment of their place as a practical
and reliable research approach in the palliative care
population. The availability of this information will influ-
ence research policy and change clinical practice by im-
proving availability of high quality evidence in drug
studies in difficult to recruit and/or follow patient
populations.
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